ArticlePediatric nephrology (Berlin, Germany)2026
Novel extracorporeal therapies in children.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, extracorporeal therapies have expanded beyond their traditional role in acute kidney injury (AKI), providing new possibilities for extracorporeal blood purification, immunomodulation, and organ support in critically ill children. Novel systems such as CytoSorb® and oXiris® enable extracorporeal removal of inflammatory mediators and cytokines, whereas Toraymyxin® and Seraph® target endotoxins and pathogen-associated molecules. The Selective Cytopheretic Device for Pediatrics (SCD-PED) provides immunomodulatory therapy through leukocyte modulation. These technologies are increasingly used in septic shock, cytokine storm syndromes, liver failure, intoxications, and rhabdomyolysis. Additionally, pediatric-oriented platforms such as the Newcastle Infant Dialysis Ultrafiltration System (NIDUS) address technical limitations of CKRT in neonates and low-body-weight children by minimizing extracorporeal circuit volume, whereas extracorporeal carbon dioxide removal (ECCO₂R) expands the role of extracorporeal circuits by providing respiratory support in selected cases of severe hypercapnic respiratory failure. However, pediatric evidence remains limited and is largely derived from case reports, small observational studies, and registry data. Our review summarizes mechanisms of action, current evidence, technical considerations, and limitations of emerging extracorporeal therapies, with emphasis on pediatric applicability and safety.
Indexed as
Identifiers
42455146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.